Cargando…

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease

BACKGROUND: The U.S. Preventive Services Task Force in 2009 recommended increased aspirin use for primary prevention of cardiovascular disease (CVD) in men ages 45 to 79 years and women ages 55 to 79 years for whom benefit outweighs risk. This study estimated the clinical efficacy and cost‐effective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michaud, Tzeyu L., Abraham, Jean, Jalal, Hawre, Luepker, Russell V., Duval, Sue, Hirsch, Alan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845274/ https://www.ncbi.nlm.nih.gov/pubmed/26702086 http://dx.doi.org/10.1161/JAHA.115.002321

Ejemplares similares

Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980–2009: The Minnesota Heart Survey
por: Luepker, Russell V., et al.
Publicado: (2015)

Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007—2015: A Serial, Cross‐sectional Study
por: Van't Hof, Jeremy R., et al.
Publicado: (2017)

A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease
por: Oldenburg, Niki C., et al.
Publicado: (2014)

Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease: A Nonrandomized Controlled Trial
por: Luepker, Russell V., et al.
Publicado: (2022)

News coverage and online advertising effects on patient-led search for aspirin, heart health, and stroke information and educational tool use
por: Southwell, Brian G., et al.
Publicado: (2021)

Estimation of Cardiovascular Risk from Self-Reported Knowledge of Risk Factors: Insights from the Minnesota Heart Survey
por: Duval, Sue, et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Costing a population health management approach for participant recruitment to a diabetes prevention study
por: Michaud, Tzeyu L, et al.
Publicado: (2021)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Effect of a Statewide Media Campaign on Smoking Cessation Among Florida Adults
por: Duke, Jennifer C., et al.
Publicado: (2020)

Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program
por: Krzyzanowski, Brittany, et al.
Publicado: (2019)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
por: Bem, Danai, et al.
Publicado: (2015)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
por: Amirsadri, Mohammadreza, et al.
Publicado: (2017)

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
por: Jiang, Minghuan, et al.
Publicado: (2019)

Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk
por: Smith, Lauren, et al.
Publicado: (2019)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic
por: Siegel, Arthur J.
Publicado: (2021)

Aspirin for primary prevention in the elderly
por: Saad, Marwan, et al.
Publicado: (2019)

Reach Outcomes and Costs of Different Physician Referral Strategies for a Weight Management Program Among Rural Primary Care Patients: Type 3 Hybrid Effectiveness-Implementation Trial
por: Porter, Gwenndolyn, et al.
Publicado: (2021)

Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study
por: Oldenburg, Niki C., et al.
Publicado: (2021)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
por: Cofer, Lucas B., et al.
Publicado: (2022)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention: who is the target?
por: Gatto, Laura, et al.
Publicado: (2019)

Aspirin for primary prevention: Is this the end of the road?
por: Singal, Aayush Kumar, et al.
Publicado: (2019)

Aspirin in primary prevention: USPSTF recommendations
por: Aalbers, J
Publicado: (2010)

Underutilization of Aspirin Persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease
por: Stafford, Randall S, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_uio3m9143tocs1chsht5fr0dab